# IFNGR1

Source: https://onco.cc/targets/ifngr1/  
OnCo record `ifngr1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IFNGR1 (Interferon gamma receptor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.

## Summary

Receptor subunit for interferon gamma/INFG that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation. Associates with transmembrane accessory factor IFNGR2 to form a functional receptor. Upon ligand binding, the intracellular domain of IFNGR1 opens out to allow association of downstream signalling components JAK1 and JAK2.

CIViC holds 1 clinical evidence item and 0 assertions across 2 variants, naming Ipilimumab.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: interferon gamma receptor 1; Interferon gamma receptor 1; CD119; IFNGR
- Tags: cancer-genes-wave
- Symbol: IFNGR1
- Class: other
- Biology: Receptor subunit for interferon gamma/INFG that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation. Associates with transmembrane accessory factor IFNGR2 to form a functional receptor. Upon ligand binding, the intracellular domain of IFNGR1 opens out to allow association of downstream signalling components JAK1 and JAK2. In turn, activated JAK1 phosphorylates IFNGR1 to form a docking site for STAT1. Subsequent phosphorylation of STAT1 leads to dimerisation, translocation to the nucleus, and stimulation of target gene transcription. STAT3 can also be activated in a similar manner although activation seems weaker. Location: Cell membrane (UniProt). Locus 6q23.3 (HGNC).
- Where found: Melanoma: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:5439: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5439
- UniProt P15260: https://www.uniprot.org/uniprotkb/P15260/entry
- NCBI Gene 3459: https://www.ncbi.nlm.nih.gov/gene/3459
- Ensembl ENSG00000027697: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000027697

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/)
- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)

---
JSON: https://onco.cc/api/v1/entities/ifngr1.json